Report
Olga Smolentseva

Clinical updates at AACR and cash runway into 2024

Transgene reported FY 2022 financial results and provided a corporate update. The financial figures were largely in line with expectations. The Company reported a net loss of EUR 32.8m in 2022 (vs EUR 19.5m in 2021), including an R&D spend of EUR 32.2m (vs EUR 32.9m in 2021). At the end of 2022
Underlying
Transgene Biotek

Transgene Biotek is a biotechnology company based in India. Co. is engaged in the development of therapeutic and preventative pharmaceuticals. Co. maintains a product portfolio which includes therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others. Co.'s products are categorized under 4 main technology platforms: Bio-Generic Drugs, which includes Orlistat, Tacrolimus and recombinant Erythropoietin; Novel Drug Delivery Technology for the oral delivery of protein drugs, with the first two targets being Insulin and Hep B vaccine; platforms for drugs against auto-immune diseases; and Oncology drugs encompassing RNAi technology as well as monoclonal antibodies.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch